

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				Application Number	10/600,266
				Filing Date	June 20, 2003
				First Named Inventor	Fumitoshi Asai
				Art Unit	1614
				Examiner Name	Brian Yong S. Kwon
Sheet	1	of	3	Attorney Docket Number	13509.105003US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		2,890,240	06-09-1959	Hamer et al.	
		3,235,583	02-15-1966	Edmunds	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code* - Number* - Kind Code* (if known)			
		WO 2000/066130	11-09-2000	Sanofi-Synthelabo	
		HU P1991 03745 (HU 211993)	12-02-1991	Gedeon Richter Chemical Works, Ltd.	English abstract only
		HU P1991 03746 (HU 211729)	12-02-1991	Gedeon Richter Chemical Works, Ltd.	English abstract only

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document. \*Enter the date the document was published. \*Enter the date the document was filed. \*Enter the kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is requested to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. The information will be used by the USPTO to determine whether to accept or reject the application. The information will not be distributed outside the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/600,266
(Use as many sheets as necessary)		Filing Date	June 20, 2003
Sheet	2	First Named Inventor	Fumitoshi Asai
		Art Unit	1614
		Examiner Name	Brian Yong S. Kwon
		Attorney Docket Number	13509.105003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	Asai et al., "Antithrombotic and Antiplatelet Effects of CS-747, A Novel P2Y Antagonist," <i>Thromb. Haemost.</i> 1999 (Supp) p. 829		T <sup>2</sup>
	Born et al., "Aspirin versus clopidogrel: the wrong question?" <i>The Lancet</i> , 349, 1997, p. 806-7, March 15, 1997		
	Kolansky et al., "Combination Therapy with Clopidogrel and Aspirin After Coronary Stenting," <i>Catheter Cardiovasc Interv.</i> , vol. 50, 276-279 (2000)		
	Leon et al., "A Clinical Trial Comparing Three Antithrombotic-drug Regimens After Coronary-Artery Stenting," <i>New England Journal of Medicine</i> , vol. 339, no. 23, pp. 1665-1671, December 3, 1998.		
	Martindale, "The Extra Pharmacopeia," 31st edition, pp. 17-22, 1996		
	Moussa, "Effectiveness of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin in Preventing Stent Thrombosis After Coronary Stent Implantation," <i>Circulation</i> , 99, 2364-2366, May 11, 1999.		
	Müller et al., "A Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary-Artery Stents," <i>Circulation</i> ; vol. 101, pp. 590-593, 2000		
	Press Release of Eli Lilly and Sankyo of December 21, 2000, Chemie.DE Information Service		
	Quinn et al., "Ticlopidine and Clopidogrel," <i>Circulation</i> , vol. 100, 1667-1672, Oct. 12, 1999.		
	Rupprecht et al., "Comparison of Antiplatelet Effects of Aspirin, Ticlopidine, or Their Combination After Stent Implantation," <i>Circulation</i> , 1998, 97, pp. 1046-1052		
	Savi et al., "Identification and Biological Activity of the Active Metabolite of Clopidogrel," <i>Thromb. Haemost.</i> , 2000, 84, pp. 891-896		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). See Kinds of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the issue of the original of the record of the Emperor must precede the serial number of the patent document. \*Kind of communication: Initial if communication is a response to a previous communication. \*Applicant's unique response number (optional).   
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is in the line (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. You are not required to respond to this collection of information unless it is displayed on a form or otherwise required by law. Your response to this collection is voluntary. We use the information to better serve you. Please contact the USPTO's Office of the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/600,266
				<i>Filing Date</i>	June 20, 2003
				<i>First Named Inventor</i>	Fumitoshi Asai
				<i>Art Unit</i>	1614
<i>(Use as many sheets as necessary)</i>				<i>Examiner Name</i>	Brian Yong S. Kwon
Sheet	3	of	3	<i>Attorney Docket Number</i>	13509.105003US

Examiner		Date	
----------	--	------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation and description number (optional): *See kinds of Codes of USPTO and USPTO's unique citation numbers at uspto.gov/apply or MPEP 609.* **Entity:** Office that issued the communication. **Applicant:** Name of the individual or entity that filed the application. **Priority:** Date of filing the application. **Language:** Language of the application. **Kind of document:** Kind of document by the appropriate symbols as indicated on the document under USPTO Standard ST. 16 if possible. **Applicant:** Is there a place to check mark here if English language Translation is attached. The collection of information is required by 37 CFR 1.70 and 1.98. This information is required to obtain or retain a benefit which is in file (or by the USPTO to process) an application. Confidentiality is granted by 35 U.S.C. 122, 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Total time varies by the complexity of the information on the amount of time you require to complete the application and any other suggestions for reducing this burden, should be sent to the Chief Information Officer for Patent and Trademark Office, US Department of Commerce, P.O. Box 4500, Alexandria, VA 22313-4560. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.